Enovis reports 2025 sales up 7% to $2.2 billion; $1.05 billion impairment drives loss
Enovis reported full-year 2025 net sales of $2.2 billion, up 7% on a reported basis, but a $1.05 billion non-cash goodwill impairment pushed its net loss from continuing operations to $1,182 million. The company also gave 2026 guidance of $2.31-2.37 billion in revenue, $425-435 million in adjusted EBITDA and $3.52-3.73 in adjusted earnings per share, which shareholders can compare with the 2025 results.
Key points
- Full-year 2025 net sales of $2.2 billion grew 7% reported and 6% organically; Recon rose 10% and Prevention & Recovery rose 4%.
- Full-year 2025 net loss from continuing operations was $1,182 million, including a $1,050 million non-cash goodwill impairment charge.
- Full-year 2025 adjusted earnings per diluted share were $3.30, compared with $2.84 in 2024; GAAP loss was $20.72 per share.
- 2026 outlook: revenue of $2.31-2.37 billion, adjusted EBITDA of $425-435 million and adjusted EPS of $3.52 to $3.73.
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.